<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37689662</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1465-993X</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Respiratory research</Title><ISOAbbreviation>Respir Res</ISOAbbreviation></Journal><ArticleTitle>A prognostic model for systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study.</ArticleTitle><Pagination><StartPage>220</StartPage><MedlinePgn>220</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">220</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12931-023-02522-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pulmonary arterial hypertension is a major cause of death in systemic lupus erythematosus, but there are no tools specialized for predicting survival in systemic lupus erythematosus-associated pulmonary arterial hypertension.</AbstractText><AbstractText Label="RESEARCH QUESTION" NlmCategory="OBJECTIVE">To develop a practical model for predicting long-term prognosis in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A prognostic model was developed from a multicenter, longitudinal national cohort of consecutively evaluated patients with systemic lupus erythematosus-associated pulmonary arterial hypertension. The study was conducted between November 2006 and February 2020. All-cause death was defined as the endpoint. Cox regression and least absolute shrinkage and selection operators were used to fit the model. Internal validation of the model was assessed by discrimination and calibration using bootstrapping.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 310 patients included in the study, 81 (26.1%) died within a median follow-up of 5.94&#xa0;years (interquartile range 4.67-7.46). The final prognostic model included eight variables: modified World Health Organization functional class, 6-min walking distance, pulmonary vascular resistance, estimated glomerular filtration rate, thrombocytopenia, mild interstitial lung disease, N-terminal pro-brain natriuretic peptide/brain natriuretic peptide level, and direct bilirubin level. A 5-year death probability predictive algorithm was established and validated using the C-index (0.77) and a satisfactory calibration curve. Risk stratification was performed based on the predicted probability to improve clinical decision-making.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This new risk stratification model for systemic lupus erythematosus-associated pulmonary arterial hypertension may provide individualized prognostic probability using readily obtained clinical risk factors. External validation is required to demonstrate the accuracy of this model's predictions in diverse patient populations.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Jingge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science and Technology, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengtao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science and Technology, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China. mengtao.li@cstar.org.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Guangdong General Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Miaojia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Xiaoxia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, PLA Specialized Research Institute of Rheumatology and Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, School of Medicine, Shanghai Jiao Tong University, Ren Ji Hospital South Campus, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, School of Medicine, Ren Ji Hospital, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Wufang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Central Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhuoli</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Jieruo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Junyan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science and Technology, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science and Technology, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jiuliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science and Technology, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science and Technology, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yongtai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Sciences, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Zhuang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Sciences, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanhong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Bio-Statistics, Institute of Basic Medical Sciences, China Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Tianjin Medical University General Hospital, No. 154 Anshan Street, Tianjin, 300052, China. tjweiwei2003@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science and Technology, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China. zengxfpumc@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021YFC2501300</GrantID><Agency>Chinese National Key Technology R&amp;D Program, Ministry of Science and Technology</Agency><Country/></Grant><Grant><GrantID>No.Z201100005520022,23, 25-27</GrantID><Agency>Beijing Municipal Science &amp; Technology Commission</Agency><Country/></Grant><Grant><GrantID>82241019</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82271855</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81900054</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2021-I2M-1-005</GrantID><Agency>CAMS Innovation Fund for Medical Sciences (CIFMS)</Agency><Country/></Grant><Grant><GrantID>2022-PUMCH-B-013, C-002, D-009</GrantID><Agency>National High Level Hospital Clinical Research Funding</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Res</MedlineTA><NlmUniqueID>101090633</NlmUniqueID><ISSNLinking>1465-9921</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081029" MajorTopicYN="Y">Pulmonary Arterial Hypertension</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065627" MajorTopicYN="N">Familial Primary Pulmonary Hypertension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Pulmonary arterial hypertension</Keyword><Keyword MajorTopicYN="N">Risk stratification</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors have declared no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>10</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37689662</ArticleId><ArticleId IdType="pmc">PMC10492375</ArticleId><ArticleId IdType="doi">10.1186/s12931-023-02522-2</ArticleId><ArticleId IdType="pii">10.1186/s12931-023-02522-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fei Y, Shi X, Gan F, Li X, Zhang W, Li M, Hou Y, Zhang X, Zhao Y, Zeng X, Zhang F. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years. Clin Rheumatol. 2014;33(1):57&#x2013;63. doi: 10.1007/s10067-013-2383-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-013-2383-3</ArticleId><ArticleId IdType="pubmed">24046218</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan IS, Mensah KA, Rudkovskaia AA, Adonteng-Boateng PK, Herzog EL, Buckley L, Fares WH. Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: a review. Respir Med. 2018;134:42&#x2013;46. doi: 10.1016/j.rmed.2017.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2017.11.020</ArticleId><ArticleId IdType="pubmed">29413506</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Wang Q, Liu Y, Tian Z, Guo X, Wang H, Lai J, Huang C, Yang X, Li M, Zeng X. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China. Int J Cardiol. 2017;236:432&#x2013;437. doi: 10.1016/j.ijcard.2017.01.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2017.01.097</ArticleId><ArticleId IdType="pubmed">28159359</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung L, Kawut SM. Connective tissue disease-associated pulmonary arterial hypertension: &#x201c;Beijing style&#x201d;. Eur Respir J. 2014;44(4):839&#x2013;841. doi: 10.1183/09031936.00090814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00090814</ArticleId><ArticleId IdType="pubmed">25271223</ArticleId></ArticleIdList></Reference><Reference><Citation>Gali&#xe8; N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Eur Respir J. 2016;46(4):903&#x2013;975. doi: 10.1183/13993003.01032-2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01032-2015</ArticleId><ArticleId IdType="pubmed">26318161</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618&#x2013;3731. doi: 10.1093/eurheartj/ehac237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac237</ArticleId><ArticleId IdType="pubmed">36017548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, Olsson KM, Meyer K, Vizza CD, Vonk-Noordegraaf A, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Huscher D, Pittrow D, Rosenkranz S, Gr&#xfc;nig E. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):1700740. doi: 10.1183/13993003.00740-2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00740-2017</ArticleId><ArticleId IdType="pubmed">28775047</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Ya&#xef;ci A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Ja&#xef;s X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156&#x2013;163. doi: 10.1161/CIRCULATIONAHA.109.911818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.911818</ArticleId><ArticleId IdType="pubmed">20585011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kylhammar D, Kjellstr&#xf6;m B, Hjalmarsson C, Jansson K, Nisell M, S&#xf6;derberg S, Wikstr&#xf6;m G, R&#xe5;degran G. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175&#x2013;4181. doi: 10.1093/eurheartj/ehx257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx257</ArticleId><ArticleId IdType="pubmed">28575277</ArticleId></ArticleIdList></Reference><Reference><Citation>Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation. 2010;122(2):164&#x2013;172. doi: 10.1161/CIRCULATIONAHA.109.898122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.898122</ArticleId><ArticleId IdType="pubmed">20585012</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol. 2012;2012:854941. doi: 10.1155/2012/854941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/854941</ArticleId><ArticleId IdType="pmc">PMC3318206</ArticleId><ArticleId IdType="pubmed">22489252</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Zhang W, Leng X, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Zhang F, Zhao Y, Zeng X, CSTAR co-authors Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus. 2013;22(11):1192&#x2013;1199. doi: 10.1177/0961203313499086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313499086</ArticleId><ArticleId IdType="pubmed">23963101</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Tian X, Zhang W, Leng X, Zeng X. CRDC: a Chinese rheumatology research platform. Clin Rheumatol. 2015;34(8):1347&#x2013;1352. doi: 10.1007/s10067-015-3003-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-3003-1</ArticleId><ArticleId IdType="pubmed">26160265</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Wang Q, Zhao J, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Tian Z, Liu Y, He J, Zhang F, Zhao Y, Zeng X, CSTAR co-authors Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus. 2014;23(10):1085&#x2013;1091. doi: 10.1177/0961203314527366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314527366</ArticleId><ArticleId IdType="pubmed">24651670</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, Wei W, Zuo X, Zhang M, Zhu P, Ye S, Zhang W, Zheng Y, Qi W, Li Y, Zhang Z, Ding F, Gu J, Liu Y, Wang Y, Zeng X, following investigators were collaborators in the CSTAR-PAH study Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J. 2019;53(2):1800081. doi: 10.1183/13993003.00081-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00081-2018</ArticleId><ArticleId IdType="pubmed">30635295</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594. doi: 10.1136/bmj.g7594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7594</ArticleId><ArticleId IdType="pubmed">25569120</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwar M, Raina A, Lohmueller L, Kraisangka J, Benza R. The use of risk assessment tools and prognostic scores in managing patients with pulmonary arterial hypertension. Curr Hypertens Rep. 2019;21(6):45. doi: 10.1007/s11906-019-0950-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-019-0950-y</ArticleId><ArticleId IdType="pmc">PMC6756754</ArticleId><ArticleId IdType="pubmed">31025123</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Wang Y, Huang C, Yang X, Zhao J, Wang Q, Tian Z, Li M, Zeng X. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev. 2016;15(3):250&#x2013;257. doi: 10.1016/j.autrev.2015.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.11.012</ArticleId><ArticleId IdType="pubmed">26640159</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Ioannidis JPA, van Calster B, Collaborators Poor performance of clinical prediction models: the harm of commonly applied methods. J Clin Epidemiol. 2018;98:133&#x2013;143. doi: 10.1016/j.jclinepi.2017.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2017.11.013</ArticleId><ArticleId IdType="pubmed">29174118</ArticleId></ArticleIdList></Reference><Reference><Citation>Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343&#x2013;346. doi: 10.1016/0197-2456(96)00075-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(96)00075-X</ArticleId><ArticleId IdType="pubmed">8889347</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6):681&#x2013;694. doi: 10.1002/(SICI)1097-0258(19990330)18:6&lt;681::AID-SIM71&gt;3.0.CO;2-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19990330)18:6&lt;681::AID-SIM71&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">10204197</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377&#x2013;399. doi: 10.1002/sim.4067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4067</ArticleId><ArticleId IdType="pubmed">21225900</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley Classics Library; 2004.</Citation></Reference><Reference><Citation>Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385&#x2013;395. doi: 10.1002/(SICI)1097-0258(19970228)16:4&lt;385::AID-SIM380&gt;3.0.CO;2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19970228)16:4&lt;385::AID-SIM380&gt;3.0.CO;2-3</ArticleId><ArticleId IdType="pubmed">9044528</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox D. Regression models and life tables. J Royal Stat Soc B. 1972;34:187&#x2013;200.</Citation></Reference><Reference><Citation>Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239&#x2013;241. doi: 10.1093/biomet/69.1.239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/69.1.239</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774&#x2013;781. doi: 10.1016/S0895-4356(01)00341-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(01)00341-9</ArticleId><ArticleId IdType="pubmed">11470385</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361&#x2013;87. doi: 10.1002/(SICI)1097-0258(19960229)15:4&lt;361::AID-SIM168&gt;3.0.CO;2-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19960229)15:4&lt;361::AID-SIM168&gt;3.0.CO;2-4</ArticleId><ArticleId IdType="pubmed">8668867</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier G. Verification of forecasts expressed in terms of probability. Mon Weather Rev. 1950;78:1&#x2013;3. doi: 10.1175/1520-0493(1950)078&lt;0001:VOFEIT&gt;2.0.CO;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1175/1520-0493(1950)078&lt;0001:VOFEIT&gt;2.0.CO;2</ArticleId></ArticleIdList></Reference><Reference><Citation>Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, McGinn T, Guyatt G. Discrimination and calibration of clinical prediction models: users' guides to the medical literature. JAMA. 2017;318(14):1377&#x2013;1384. doi: 10.1001/jama.2017.12126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.12126</ArticleId><ArticleId IdType="pubmed">29049590</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW, Topic Group &#x2018;Evaluating diagnostic tests and prediction models&#x2019; of the STRATOS initiative Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17(1):230. doi: 10.1186/s12916-019-1466-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1466-7</ArticleId><ArticleId IdType="pmc">PMC6912996</ArticleId><ArticleId IdType="pubmed">31842878</ArticleId></ArticleIdList></Reference><Reference><Citation>Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch DB, McGoon MD. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354&#x2013;62. doi: 10.1378/chest.11-0676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-0676</ArticleId><ArticleId IdType="pubmed">21680644</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemari&#xe9; JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015;46(1):152&#x2013;164. doi: 10.1183/09031936.00004414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00004414</ArticleId><ArticleId IdType="pubmed">25837032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogswell R, McGlothlin D, Kobashigawa E, Shaw R, De Marco T. Performance of the REVEAL model in WHO Group 2 to 5 pulmonary hypertension: application beyond pulmonary arterial hypertension. J Heart Lung Transplant. 2013;32(3):293&#x2013;298. doi: 10.1016/j.healun.2012.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2012.11.012</ArticleId><ArticleId IdType="pubmed">23265906</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J, Li M, Zeng X, Zhang X, Wei W, Zuo X, et al. Validation of the REVEAL Prognostic Models in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. Front Med (Lausanne) 2021;8:618486. doi: 10.3389/fmed.2021.618486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.618486</ArticleId><ArticleId IdType="pmc">PMC7969505</ArticleId><ArticleId IdType="pubmed">33748158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grunig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260123</ArticleId><ArticleId IdType="pubmed">34737226</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucly A, Weatherald J, Savale L, Ja&#xef;s X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E, Chaouat A, Chabanne C, Bourdin A, Parent F, Montani D, Simonneau G, Humbert M, Sitbon O. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi: 10.1183/13993003.00889-2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00889-2017</ArticleId><ArticleId IdType="pubmed">28775050</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2018;37(6):696&#x2013;705. doi: 10.1016/j.healun.2017.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2017.10.028</ArticleId><ArticleId IdType="pubmed">29174533</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015;34(3):362&#x2013;368. doi: 10.1016/j.healun.2014.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2014.08.020</ArticleId><ArticleId IdType="pubmed">25312386</ArticleId></ArticleIdList></Reference><Reference><Citation>Querejeta Roca G, Campbell P, Claggett B, Vazir A, Quinn D, Solomon SD, Shah AM. Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. Eur J Heart Fail. 2015;17(1):63&#x2013;73. doi: 10.1002/ejhf.177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.177</ArticleId><ArticleId IdType="pmc">PMC5551563</ArticleId><ArticleId IdType="pubmed">25367310</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda Y, Takeda Y, Tomimoto S, Tani T, Narita H, Kimura G. Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm Med. 2010;10:22. doi: 10.1186/1471-2466-10-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2466-10-22</ArticleId><ArticleId IdType="pmc">PMC2873470</ArticleId><ArticleId IdType="pubmed">20412580</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu XQ, Lv ZC, Liu QQ, Zhao QH, Wu Y, Sun K, Jiang X, Wang L, Peng FH, Jing ZC. Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension. Int J Cardiol. 2017;228:895&#x2013;899. doi: 10.1016/j.ijcard.2016.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.11.036</ArticleId><ArticleId IdType="pubmed">27894061</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Gali&#xe8; N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF. Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension. Circulation. 2019;139(21):2440&#x2013;50. doi: 10.1161/CIRCULATIONAHA.118.039360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.039360</ArticleId><ArticleId IdType="pmc">PMC6530970</ArticleId><ArticleId IdType="pubmed">30982349</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, Zhao C, Mink DR, Selej M, Benza RL. Baseline and serial brain natriuretic peptide level predicts 5-year overall survival in patients with pulmonary arterial hypertension: Data From the REVEAL Registry. Chest. 2018;154(1):126&#x2013;135. doi: 10.1016/j.chest.2018.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.01.009</ArticleId><ArticleId IdType="pmc">PMC6859253</ArticleId><ArticleId IdType="pubmed">29355551</ArticleId></ArticleIdList></Reference><Reference><Citation>Kommireddy S, Bhyravavajhala S, Kurimeti K, Chennareddy S, Kanchinadham S, Rajendra Vara Prasad I, Rajasekhar L. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology (Oxford) 2015;54(9):1673&#x2013;1679. doi: 10.1093/rheumatology/kev097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev097</ArticleId><ArticleId IdType="pubmed">25929760</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>